title: Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on high-flux haemodialysis and human recombinant erythropoietin.
abstract: BACKGROUND
  High-flux haemodialysis (HD) has recently been vigorously promoted as a novel standard, and it can indeed efficiently reduce the occurrence of most uraemic symptoms due to middle molecular toxins and/or underdialysis. However, some symptoms remain problematical, particularly peripheral polyneuropathy (PPN). One of the possible reasons for this is that the patients may have low concentrations of some nutrients, e.g. vitamin B(6), necessary for normal peripheral neuron function.
  
  
  METHODS
  Predialysis serum pyridoxal-5'-phosphate (P5P) level was determined in 36 chronic HD patients who were undergoing high-flux HD and receiving human recombinant erythropoietin. Among them, 26 patients suffered from PPN. Prior to supplementation, these 26 patients were examined and their neurological symptoms were ranked according to our PPN symptom score. Vitamin B(6) (60 mg/day) was randomly prescribed to 14 of them, and vitamin B(12) (500 microg/day) was prescribed to the others. After 4 weeks, all the patients were re-examined.
  
  
  RESULTS
  We found that predialysis serum P5P levels of HD patients with PPN were not significantly lower than those of matched HD patients without PPN. Nonetheless, it was demonstrated that supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P and dramatically attenuated PPN symptoms compared with initial symptoms. No improvement was observed in response to vitamin B(12) supplementation.
  
  
  CONCLUSIONS
  This result suggests that although vitamin B(6) deficiency could not be demonstrated in patients with chronic renal failure on high-flux HD, vitamin B(6) supplementation was effective in improving PPN symptoms of various aetiologies, possibly because of vitamin B(6) resistance to PPN in these patients.
authors.affiliation: Department of Nephrology, Saitama Medical College, Irumagun, Saitama, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Moriwaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kanno
authors.forename: S
authors.initials: S
authors.lastname: Sugahara
authors.forename: H
authors.initials: H
authors.lastname: Nakamoto
authors.forename: M
authors.initials: M
authors.lastname: Yoshizawa
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D002908:Chronic Disease; D003929:Diabetic Neuropathies / Q000188:drug therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011115:Polyneuropathies / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D011732:Pyridoxal Phosphate / Q000097:blood; D011736:Pyridoxine / Q000627:therapeutic use*; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000379:methods*; D014805:Vitamin B 12 / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D011732:Pyridoxal Phosphate; D011736:Pyridoxine; D014805:Vitamin B 12